Odgovor: |
NCBI - Pub.med (30.10.2018.):
- Bowling, JCR et al. Raynaud's disease. The Lancet , Volume 361 , Issue 9374 , 2078 - 2080
- Saigal R, Kansal A, Mittal M, Singh Y, Ram H. Raynaud's phenomenon. J Assoc Physicians India. 2010 May;58:309-13.
- Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638.
- Martine Gayraud. Raynaud’s phenomenon. Joint Bone Spine. 2007 Jan;74(1):e1-8. Epub 2006 Dec 4.
Research Gate (2018-10-30):
- Levien, Terri. (2010). Advances in the treatment of Raynaud’s phenomenon. Vascular health and risk management. 6. 167-77. 10.2147/VHRM.S4551.
- Fardon, Manal & Nassif, Joseph & Issa, Khodor & Baydoun, Elias & Eid, Ali. (2016). Raynaud’s Phenomenon: A Brief Review of the Underlying Mechanisms. Frontiers in Pharmacology. 7. 10.3389/fphar.2016.00438.
EBSCO Host (pristup u GISKO ili putem NSK Portala elektroničkih izvora):
- Górska, K. et al. (2017) ‘Raynaud’s phenomenon as an interdisciplinary problem’, Dermatology Review / Przeglad Dermatologiczny, 104(5), pp. 499–508. doi: 10.5114/dr.2017.71215.
- Walecka, I. et al. (2017) ‘Raynaud’s phenomenon -- the clinical picture, treatment and diagnostics’, Acta Angiologica, 23(1), pp. 29–33. doi: 10.5603/AA.2017.0003.
- Zhang, X. et al. (2015) ‘Treatment of Raynaud’s phenomenon with botulinum toxin type A’, Neurological Sciences, 36(7), pp. 1225–1231. doi: 10.1007/s10072-015-2084-6.
|